GlassScriptPhysician profile
Richard Samuel
NPI 1760436505
$1,658.52
in general payments reported to CMS, 2019-2025
14 companies · $989 in 2025
The $989 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $669 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.44 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.93 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $209.36 | 2024-2025 | |
| Exact Sciences Corporation | $205.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $187.31 | 2024-2025 | Jardiance, Kisunla, Zepbound |
| Amgen INC. | $100.97 | 2024-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $80.43 | 2024-2025 | Capvaxive, Gardasil 9, Lagevrio |
| Glaxosmithkline, LLC. | $71.80 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $59.79 | 2025 | |
| Astellas Pharma US INC | $49.47 | 2024-2025 | Veozah |
| Abbott Laboratories | $42.36 | 2024-2025 | Freestyle Libre 3 |
| Becton, Dickinson and Company | $24.98 | 2025 | Bd Max System, Bd Max Instrument |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.63 | 2024 | Jardiance, Tradjenta |
| Gilead Sciences, INC. | $14.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.